Silence Therapeutics CEO Dismisses Alnylam's Criticism of Zamore Patent Portfolio

Philip Haworth also said that the company does not agree that Alnylam's own IP estate is as dominant as it portrays it to be, and that "we've never believed there will be a single party from whom all [RNAi therapeutics] flow."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories